TELA Bio launches OviTex IHR for inguinal hernia repair in U.S.

TELA Bio, Inc.

OviTex IHR targets over 665,000 annual U.S. inguinal hernia procedures; three configurations available.
Builds on OviTex portfolio with >45,000 implantations and 8 years clinical experience.
Study on 259 patients using ReBAR technique showed low 1.2% recurrence rate at 1.5-year follow-up.
Designed for laparoscopic and robotic-assisted repair; aims to address shortcomings of permanent synthetic mesh.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.